Nuclear Factor-κB-inducing Kinase (NIK) Contains an Amino-terminal Inhibitor of Apoptosis (IAP)-binding Motif (IBM) That Potentiates NIK Degradation by Cellular IAP1 (c-IAP1)*

Received for publication, June 6, 2014, and in revised form, September 3, 2014. Published, JBC Papers in Press, September 22, 2014, DOI 10.1074/jbc.M114.587808

Sunhee Lee‡, Madhavi Challa-Malladi†, Shawn B. Bratton‡¶, and Casey W. Wright‡*‡

From†The Center for Molecular and Cellular Toxicology in the Division of Pharmacology and Toxicology, College of Pharmacy and ‡The Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, Texas 78712, and the *Department of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville, Texas 78957

Background: NIK stability is necessary for activation of the noncanonical NF-κB pathway.

Results: The N terminus of NIK harbors an IBM that binds to c-IAP1 and promotes NIK degradation.

Conclusion: The NIK IBM provides substrate recognition for c-IAP1 activity to maximize the suppression of noncanonical NF-κB signaling.

Significance: This study reveals new mechanistic insight into the regulation of the c-IAP TRAF2/3-NIK complex.

Activation of the noncanonical NF-κB pathway hinges on the stability of the NF-κB-inducing kinase (NIK), which is kept at low levels basally by a protein complex consisting of the E3 ubiquitin ligases cellular inhibitor of apoptosis 1 and 2 (c-IAP1/2) proteins and the tumor necrosis factor receptor-associated factors 2 and 3 (TRAF2/3). NIK is brought into close proximity to the c-IAPs through a TRAF2-TRAF3 bridge where TRAF2 recruits c-IAP1/2 and TRAF3 binds to NIK. However, it is not clear how the c-IAPs specifically recognize and ubiquitylate NIK in the complex. We have identified an IAP-binding motif (IBM) at the amino terminus of NIK. IBMs are utilized by a number of proapoptotic proteins to antagonize IAP function. Here, we utilize mutational studies to demonstrate that wild-type NIK is destabilized in the presence of c-IAP1, whereas the NIK IBM mutant is stable. NIK interacts with the second baculovirus IAP repeat (BIR2) domain of c-IAP1 via the IBM, and this interaction, in turn, provides substrate recognition for c-IAP1-mediated ubiquitylation and degradation of NIK. Furthermore, in the presence of the NIK IBM mutant, we observed an elevated processing of p100 to p52 followed by increased expression of NF-κB target genes. Together, these findings reveal the novel identification and function of the NIK IBM, which promotes c-IAP1-dependent ubiquitylation of NIK, resulting in optimal NIK turnover to ensure that noncanonical NF-κB signaling is off in the absence of an activating signal.

The transcription factor, nuclear factor-κB (NF-κB), plays an important role in the maintenance and activation of leukocytes following an immune response (1). Thus, tight control of NF-κB is critical for the proper homeostatic function of many processes of innate immunity, especially the inflammatory response, and for activation of B and T cells during the adaptive immune response. Gene regulation by the NF-κB family of transcription factors is accomplished through differential dimerization of five discrete NF-κB subunits known as RelA, RelB, c-Rel, p50/p105, and p52/p100, which homodimerize or heterodimerize to form active transcription factors with different target gene specificities (2). Regulated processing of the larger precursor proteins p105 and p100 yields the transcriptionally functional p50 and p52 subunits, respectively. In quiescent cells, preformed NF-κB dimers are sequestered in the cytoplasm by a family of NF-κB inhibitory proteins (IκBs). Nuclear translocation of the NF-κB dimers is governed by one of two regulatory kinase cascades, depending on the stimulus, referred to as the canonical and noncanonical pathways of NF-κB signaling.

Activation of the canonical pathway occurs downstream of the Toll-like receptors, the T and B cell receptors, and tumor necrosis factor receptors 1 and 2 (3, 4). After the cell receives a stimulus, IκB is targeted by an IκB kinase (IKK) complex consisting of IKKa, IKKB, and NF-κB essential modulator (NEMO), leading to ubiquitylation and proteosomal degradation of IκB, allowing for nuclear translocation of RelA, p50 and c-Rel, p50 dimers. Alternatively, the noncanonical NF-κB pathway is activated downstream of a subset of TNF receptor family members, including LTβR, BAFFR, CD40, and CD30 (5–7). NF-κB-inducing kinase (NIK) is required for stimulation of the noncanonical NF-κB pathway and, under basal conditions, is continuously targeted for proteosomal degradation by an E3 ubiquitin ligase complex consisting of the cellular inhibitor of apoptosis 1 and 2 (c-IAP1 and c-IAP2) proteins and the TNF receptor-associated factors 2 and 3 (TRAF2 and TRAF3) (8, 9).
Initiation of noncanonical NF-κB signaling results in disassembly of the complex and accumulation of NIK through c-IAP-mediated auto-degradation or degradation of TRAF2 and TRAF3, depending on the activating receptor (10). Stabilized NIK takes an active conformation, without the need for phosphorylation, and proceeds to phosphorylate and activate IKKα (11). In turn, IKKα phosphorylates the carboxyl-terminal 1κB domain of the p100 precursor protein resulting in processing to allow p52-RelB dimers to translocate to the nucleus (12).

IAP proteins are members of a family defined by the presence of one or more baculovirus IAP repeat (BIR) domains (13, 14). Although the importance of IAPs in immune signaling is now appreciated, they were initially described, as their name implies, as modulators of apoptotic signaling (14). Most notably, X-linked IAP (XIAP) was found to selectively bind to and directly inhibit the proteolytic activities of caspases-3, -7 and -9 through its linker-BIR2 and BIR3 domains, respectively (14). In each instance, initial cleavage of the intersubunit linker, separating the large and small subunits of the caspase, resulted in the exposure of a neoepitope on the N terminus of the small subunit, known as an IAP binding motif (IBM), that inserted into a pocket in the BIR domain (14). Similar IBMs are present within many IAP-binding proteins, most of which share no homology outside of a conserved N-terminal tetrapeptide sequence that is exposed during protein maturation. Similar to XIAP, c-IAPs also contain BIR domains that can bind to caspases, but rather than directly inhibiting their catalytic activities, they instead efficiently ubiquitylate caspases and target them for destruction via the proteasome (15, 16). When overexpressed, c-IAPs may also block cell death by acting as sinks for IAP antagonists such as second mitochondrial activator of caspasess (Smac; also known as DIABLO), which generally promote apoptosis by displacing active caspases from XIAP (17–20).

As alluded to above, the majority of the IAP proteins also display intrinsic E3 ubiquitin ligase activity via their RING domains (16, 21–23), and it is this activity that is thought to mediate their crucial roles in various signal transduction pathways. The E3 ubiquitin ligase activity of c-IAPs can also be modulated by their interactions with IBM-containing proteins (24). For example, during apoptosis, the release of mature Smac from mitochondria into the cytoplasm facilitates the interaction of the Smac IBM with IAPs. In addition to displacing caspases from IAPs, Smac (or Smac mimetic drugs) also promotes autoubiquitylation of c-IAP1/2, which stabilizes NIK and activates the noncanonical NF-κB signaling pathway (24, 25).

In the current study, we have identified the presence of an IBM sequence at the N terminus of NIK and demonstrate that the NIK IBM is necessary for efficient c-IAP1-dependent ubiquitylation of NIK. Thus, the directed targeting of NIK ensures its maximal degradation, in turn suppressing downstream p100 processing and the transcriptional activation of NF-κB target genes. These findings are significant as they define a key regulatory element of the c-IAP-TRAF2-TRAF3-NIK complex.

**EXPERIMENTAL PROCEDURES**

**Cell Culture and Reagents**—Human embryonic kidney (HEK) 293T cells were grown in DMEM supplemented with 10% fetal bovine serum (Atlas Biologicals, Inc.), 2 mM Glutamax (Invitrogen), penicillin (100 units/ml), and streptomycin (100 μg/ml). Cells were maintained at 37 °C and 5% CO2.

**Antibodies and Immunoblotting**—Cell lysates were prepared by incubating cells on ice in radioimmuno precipitation assay buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM EDTA, 1 mM PMSF, and 1 mM DTT) supplemented with complete mini protease inhibitor tablets (Roche Diagnostics). Protein samples were normalized by Bradford assay (Bio-Rad), resolved on denaturing polyacrylamide gels, and transferred to nitrocellulose membrane (Whatman). Membranes were blocked with 5% milk (w/v) in TBS containing 0.1% Tween 20 (Fisher) and incubated with the specified primary antibodies, washed, and incubated with horseradish peroxidase (HRP)-conjugated anti-mouse IgG or anti-rabbit IgG secondary antibodies (GE Healthcare). Peroxidase activity was detected by using enhanced chemiluminescence (GE Healthcare). Equal loading of protein samples was confirmed by blotting membranes with β-actin antibody. Antibodies used for immunoblotting: NIK (H-248), TRAF2 (C-20), TRAF3 (G-6), GST (Z-5) (Santa Cruz Biotechnologies); TRAF2 (BD Pharmingen); FLAG-HRP, HA-HRP, FLAG M2, and β-actin (Sigma); GFP (Novus).

**Plasmids**—To ensure exposure of the NIK IBM in our ectopic expression experiments, we generated a DHFR-HA-Ub-NIK-EGFP fusion construct as follows. First, using the pDHuUbXeK1βgal plasmid as template (kindly provided by A. Varshavsky), a cDNA for mouse dihydrofolate reductase (DHFR) fused to an HA tag and a ubiquitin (K48R) moiety was obtained by PCR and cloned into the Nhel/BglII sites of pEFGP-N1 (26). Full-length NIK was then cloned into BglIII/EcoRI, and the BglII site was removed by site-directed mutagenesis to ensure that glycine 76 of ubiquitin immediately preceded alanine 2 of NIK with no intervening sequences, thereby ensuring that deubiquitinases would cleave DHFR-HA-Ub from the NIK-EGFP during translation and exposure of alanine 2 of NIK. The NIK IBM mutant (A2G/V3G) was then generated by QuikChange site-directed mutagenesis (Agilent Technologies) following the manufacturer’s instructions and using primer sequences: Ub-MNIK (A2G/V3G)-GFP, 5’-GAG GTG GTA TGG GAG GGA TGG AAA TGG-3’ (forward) and 5’-CCA TTT CCA TCC TCT CCA TAC CAC CTC-3’ (reverse); and Ub-NIK (A2G/V3G)-GFP, 5’-CTA AGA GGT GGT GGA GTG AAG ATG-3’ (forward) and 5’-CTT TTC CAT CCC TCC ACC ACC TCT TAG-3’ (reverse). For expression of the individual BIR domains, BIR1, -2, and -3 of c-IAP1 were amplified by PCR using Phusion polymerase (New England Biolabs), and the resultant PCR products were subcloned into pEBG. The amplification and cloning of the BIR domains have been described (27). pEVB FLAG-clAP1, pEVB FLAG-clAP1 (H588A), pEBB c-IAP1-HA, pEVB c-IAP1 (H588A)-HA, pEVB FLAG-Ub, Ub-Smac-HA, and Ub-Smac (A1G)-HA have been described (25). pEVB FLAG-NIK and pEBB NIK-FLAG were constructed by subcloning the coding sequence of NIK into the respective pEBG vector.

**Plasmid Transfection and RNA Interference**—HEK 293T cells were transfected with the indicated plasmid(s) and/or short interfering RNA using a standard calcium phosphate precipitation protocol (see figure legends for nucleic acid concentra-
The NIK IBM Provides Substrate Recognition for c-IAP1

Results

NIK Possesses an N-terminal IBM That Promotes NIK Degradation—To better understand the regulation of the c-IAP-TRAF-NIK complex, we searched for previously uncharacterized motifs and domains in NIK. Interestingly, we identified a putative IBM at the N terminus of NIK, just downstream of the initiating methionine, through sequence homology (Fig. 1A).

To test the function of the NIK IBM we mutated the position 2 alanine and position 3 valine, two amino acids that contribute significantly to the binding affinity of other IBMs to IAPs, to glycine (A2G/V3G) and asked whether NIK stability was affected in the presence of c-IAP1 (29). Wild-type (WT) NIK was degraded when ectopically expressed with c-IAP1 in HEK293T cells. However, NIK (A2G/V3G) was stabilized (Fig. 1B, compare lanes 5 and 8). As a control, a c-IAP1 RING mutant was used (H588A), which disrupts its E3 ubiquitin ligase activity and, as expected, c-IAP1 (H588A) did not show differential effects on the stability of WT or IBM mutant NIK. Similar results were obtained using c-IAP2, but it was relatively unstable compared with c-IAP1, resulting in a less dramatic affect on NIK stability (data not shown). We therefore focused our attention on c-IAP1. These results suggested that the NIK IBM was crucial for directing c-IAP1-mediated NIK degradation but were somewhat surprising since the initiator methionine in NIK would be predicted to block the c-IAP1-NIK IBM interaction. Thus, the initiator methionine of NIK was most likely removed, consistent with the propensity for methionine aminopeptidases to remove initiating methionines from proteins with less bulky amino acids in the second position (30). To test this possibility, we fused a FLAG tag to the N terminus of NIK (FLAG-NIK) to block the removal of the initiating methionine. FLAG-NIK was stable in the presence of c-IAP1, whereas a C-terminally FLAG-tagged NIK was unstable (Fig. 1C), further implying that the initiating methionine is removed to expose the NIK IBM.

To ensure processing of NIK and allow for full characterization of the NIK IBM without concern for whether or not the methionine was removed, we employed a system where ubiquitin is fused in-frame with the coding sequence for mature NIK (31). Deubiquitylating enzymes then co-translationally cleave off the ubiquitin molecule leaving the exposed NIK IBM. Using this system, we obtained similar results as those using full-length WT or IBM mutant NIK (Fig. 1, B–D). Additionally, an eGFP tag was fused to the carboxyl terminus of NIK to allow for easy monitoring of NIK stability. As shown in Fig. 1E, there was a significant increase in GFP detection in the NIK IBM mutant transfected cells as opposed to low GFP detection in the WT NIK IBM samples, when co-expressed with c-IAP1.

Data to this point suggested that the presence of WT NIH IBM directed the c-IAP1 E3 ligase activity toward NIK, resulting in degradation of NIK. To further examine whether the NIK IBM triggered ubiquitin-directed proteasomal activity, HEK293T cells were transfected with NIK-GFP or NIK (A2G/V3G)-GFP, in combination with vector, WT c-IAP1, or c-IAP1 (H588A) as a control for c-IAP1-mediated NIK degradation. Notably, cells treated with MG132 to block proteasome function confirmed that NIK was indeed degraded by the proteasome in an IBM-dependent fashion (Fig. 1F, compare lanes 2 and 8). Furthermore, using an ubiquitin immunoprecipitation experiment, we found that upon mutation of the NIK IBM a dramatic reduction of NIK ubiquitylation occurred in the presence of c-IAP1 (Fig. 1G, compare lanes 2 and 3, 6, and 7). Taken together, these results show that the NIK IBM has a key role in promoting NIK proteasomal degradation mediated by c-IAP1 E3 ubiquitin ligase activity.
The NIK IBM Is Important for Reinforcing the Interactions within the c-IAP1-TRAF2-TRAF3-NIK Complex and Is Necessary for Proper E3 Ubiquitin Ligase Targeting of NIK by c-IAP1—Based on previous studies, it is known that suppressing TRAF3 stabilizes NIK by breaking the TRAF3 bridge with TRAF2, the adapter protein responsible for c-IAP recruitment (28, 32–35). Thus, we overexpressed either the mature WT NIK-GFP or NIK (A2G/V3G)-GFP, along with control siRNA or siRNA targeted to endogenous TRAF3. Cells were also transfected with vector control, WT c-IAP1, or the E3 ligase mutant c-IAP1 (H588A) as a control for NIK degradation. Prior to TRAF3 suppression, NIK-GFP and TRAF3 were degraded in the presence of WT c-IAP1, whereas, as expected, NIK was stabilized after depletion of TRAF3 (Fig. 2A, compare lanes 2 and 5). The NIK IBM mutant, however, was stable irrespective of TRAF3 expression (Fig. 2A, compare lanes 2 and 5 with 8 and 11). Collectively, these results strongly suggested that the NIK IBM contributed to proper formation of the c-IAP1-TRAF2-TRAF3-NIK protein complex.

To further study the role of the NIK IBM in complex formation, NIK-GFP or NIK (A2G/V3G)-GFP were co-expressed with WT c-IAP1 in HEK293T cells. The stability of NIK-GFP was analyzed by fluorescence microscopy, and the nuclei of cells were visualized by Hoechst staining. The graph indicates percent of GFP positive cells. F, plasmids encoding the indicated proteins were transfected into HEK293T cells, and NIK protein levels were detected by Western blot in the presence of either c-IAP1 or c-IAP1 (H588A). To inhibit proteasomal degradation, cells were treated with MG132 (10 μM) for 6 h. The levels of NIK and c-IAP1 were analyzed by anti-GFP and anti-FLAG-HRP, respectively.
The NIK IBM Provides Substrate Recognition for c-IAP1

FIGURE 2. The NIK IBM is important for reinforcing the interactions within the c-IAP-TRAF2-TRAF3-NIK complex and is necessary for proper E3 ubiquitin ligase targeting of NIK by c-IAP1. A, HEK293T cells were transfected with TRAF3 siRNA to suppress endogenous TRAF3 expression along with plasmids encoding NIK-GFP or NIK (A2G/V3G)-GFP and FLAG-cIAP1 or FLAG-cIAP1 (H588A). Cell lysates were prepared after 48 h of incubation and analyzed by Western blot using anti-GFP, anti-TRAF3, and anti-FLAG-HRP. B, FLAG-cIAP1 constructs with either NIK-GFP or NIK (A2G/V3G)-GFP were transfected in HEK293T cells, and co-IPs were conducted using an anti-NIK antibody. Eluates were immunoblotted by anti-FLAG-HRP for detection of the c-IAP1-NIK interaction. In addition, the levels of endogenous TRAF2 and TRAF3 in the c-IAP-TRAF3-NIK complex were also analyzed by Western blot. The expression levels of NIK, cIAP1, TRAF2, and TRAF3 in input lysates were confirmed by immunoblotting with indicated antibodies. CON, control; EV, empty vector.

cells, along with either empty vector, WT c-IAP1, or c-IAP1 (H588A), followed by immunoprecipitation of NIK to isolate the c-IAP1-TRAF2-TRAF3-NIK complex (Fig. 2B). Interestingly, the endogenous TRAF proteins, along with WT NIK-GFP, were partially degraded following co-expression with WT c-IAP1, presumably by NIK IBM-directed c-IAP1 activity (Fig. 2B, lane 5, inputs). However, the small amount of WT NIK-GFP remaining was sufficient to co-immunoprecipitate the residual endogenous TRAF2 and TRAF3 (Fig. 2B, lane 5, IP). In contrast, NIK (A2G/V3G) was unable to bind TRAF2 but maintained a strong interaction with TRAF3 (Fig. 2B, compare lanes 5 and 8). Because WT c-IAP1 was unstable and difficult to detect following co-immunoprecipitation (co-IP) with WT NIK (Fig. 2B, lane 5), we also utilized the E3 ligase mutant c-IAP1 (H588A) to stabilize its expression in cells. In doing so, compared with WT NIK, the NIK IBM mutant exhibited a significant decrease in binding to c-IAP1 (H588A) and its adapter TRAF2, but not to TRAF3 (Fig. 2B, compare lanes 6 and 9). Altogether, these findings suggest that the NIK IBM further stabilizes the interactions within the c-IAP1-TRAF2-TRAF3-NIK complex apart from the TRAF bridge. Thus, the NIK IBM per se appears to mediate and perhaps even stimulate c-IAP1-dependent turnover of NIK within the complex; in its absence, c-IAP1 instead targets TRAF2 and itself for ubiquitylation and turnover. This finding is reminiscent of previous work in Drosophila, wherein DIAP1 targets BIR2-bound substrates (possessing IBMs) for ubiquitylation and turnover, but in the absence of bound substrates, instead targets itself for destruction (36).

The NIK IBM Interacts with BIR2 of c-IAP1 in a Fashion Similar to That of the Smac IBM—It is well established that IBMs bind specifically to a unique groove in the BIR domains of IAP proteins (16, 18, 19, 29, 37). To further support our hypothesis that the amino terminus of NIK is an IBM, and to identify the BIR domain(s) to which NIK binds, we performed pulldown experiments with NIK and the BIR regions of c-IAP1 (Fig. 3A). Interestingly, although mature Smac bound to BIR2 and BIR3 of c-IAP1, as expected, NIK bound specifically to BIR2 and mutation of the NIK IBM disrupted this interaction (Fig. 3, B and C). Remarkably, NIK did not interact with XIAP, regardless of the IBM status, whereas Smac interacted with XIAP in an IBM-dependent manner (Fig. 3D). These results reveal that the NIK IBM recognizes a specific BIR domain of c-IAP1 and suggests that the modest interaction observed between NIK (A2G/V3G) and c-IAP1 (H588A) (Fig. 2B) is a consequence of indirect binding mediated through the TRAF bridge.

To investigate the binding nature of the NIK IBM to c-IAP1, NIK associations with c-IAP1 were monitored by co-IP in the presence of increasing concentrations of mature Smac. Titration of mature Smac, even at the lowest transfected plasmid concentration, competitively hindered NIK from binding to c-IAP1, which was dependent on the Smac IBM (Fig. 4, A and B). To confirm that NIK was in fact interacting with the BIR2
binding pocket of c-IAP1, we mutated two key residues within the groove, aspartate 234 and glutamate 239, to alanine in the context of WT c-IAP1 (D234A/E239A) or the H588A mutant (D234A/E239A/H588A) (38). We then assessed NIK binding via co-IP, and as anticipated, found that NIK could no longer bind to c-IAP1 (D234A/E239A/H588A) and was instead stabilized (Fig. 4C, compare lanes 8 and 10, and lanes 7 and 9, Input). Combined, these data argue that NIK selectively targets distinct BIR domains within specific IAP proteins, binding in an IBM-dependent manner.

The NIK IBM Provides Substrate Recognition for c-IAP1

Co-expression of NIK-GFP alone with FLAG-p100-HA in HEK293T cells yielded the active p52 NF-κB subunit that was not present in the absence of NIK (Fig. 5A, compare lanes 2 and 5). The addition of c-IAP1 resulted in NIK degradation as shown above and diminished accumulation of p52 (Fig. 5A, compare lanes 5 and 6). However, mutation of the NIK IBM reestablished p100 processing in the presence of c-IAP1 (Fig. 5A, compare lanes 6 and 9), confirming that the NIK IBM is vital for maintaining noncanonical signaling in an off state. These results suggested that disruption of the NIK IBM might drive continuous noncanonical NF-κB activity, independent of membrane receptor-stimulation. To address this possibility, NIK or NIK (A2G/V3G) was expressed in the absence or presence of c-IAP1 after which the expression of

---

FIGURE 3. NIK IBM interacts with the BIR2 domain of c-IAP1. A, diagram of c-IAP1 constructs used in this study. The WT full-length c-IAP1 and each of the three BIR domains of c-IAP1 were fused to GST. CARD, caspase recruitment domain; RING, really interesting new gene. Interactions of BIR domains with NIK and Smac are described as the presence (+) or absence (−) of interaction. B, Smac-HA was ectopically expressed along with the individual GST-tagged BIR domains or full-length c-IAP1 in HEK293T cells. Glutathione-Sepharose (GSH) beads were used to pull down the BIRs of c-IAP1, and the eluates were probed with anti-HA-HRP to determine the presence of Smac. C, NIK-GFP or NIK (A2G/V3G)-GFP was co-expressed with each individual GST-BIR domain in HEK293T cells, and GSH beads were used to pulldown GST. The levels of NIK and BIR domains were confirmed by immunoblotting (IB) with anti-GFP and anti-GST, respectively. D, plasmids encoding NIK-GFP, NIK (A2G/V3G)-GFP, Smac-HA, Smac (A1G)-HA, and FLAG-XIAP were transfected in HEK293T cells as indicated. Cell lysates were incubated with anti-FLAG to analyze the interaction of XIAP with either NIK or Smac by co-IP.
NF-κB target genes were monitored by quantitative PCR. Expression of NIK-GFP with c-IAP1 resulted in a 2-fold reduction in expression of the indicated NF-κB target genes, compared with expression of NIK and c-IAP1 in a vector control (Fig. 5B). Interestingly, mutation of the NIK IBM rescued the expression of these genes in the presence of c-IAP1 (Fig. 5B). Collectively, our data suggest that the NIK IBM facilitates c-IAP1-mediated degradation of NIK, which suppresses p100 processing and transcriptional up-regulation of noncanonical NF-κB target genes.

DISCUSSION

In this study, we have defined the function of an IBM at the amino terminus of NIK and shown that the NIK IBM is essential for reinforcing intermolecular interactions within the c-IAP-TRAF2-TRAF3-NIK complex to allow for proper degradation of the complex under basal conditions. These findings are significant as they shed light on the molecular switch that regulates the stability of not only NIK, but also the TRAFs within the complex. Furthermore, our results reveal how loss of the NIK IBM, as occurs in certain translocation events, contributes to NIK stability. For instance, in a multiple myeloma cell line that harbors a NIK translocation that deletes the IBM and TRAF3 binding sites, NIK is still recruited into the c-IAP-TRAF2 complex through its interactions with TRAF2 but is not degraded (39). In turn, stabilized NIK activates noncanonical NF-κB signaling leading to cell survival and cancer growth, especially in B cell malignancies given the intimate integration of noncanonical signaling with B cell survival (40). This suggests that the NIK IBM is necessary to facilitate c-IAP1-mediated ubiquitylation of NIK by properly orienting NIK as the substrate.

Interestingly, it appears that the initiator methionine of NIK is removed given the fact that the WT NIK was degraded in the presence of c-IAP1, whereas an N-terminal FLAG-tagged NIK was stable. This is strikingly similar to how the IBM of the Drosophila IAP antagonists Head involution defective (Hid),...
Reaper (Rpr), and Grim are exposed, suggesting that NIK is processed in a similar fashion (36, 37, 41, 42). Once exposed, the NIK IBM binds to the second BIR of c-IAP1 to allow for maximal NIK ubiquitylation and degradation in the absence of an activating signal (Fig. 5C). Intriguingly, we found that the NIK IBM also drives degradation of TRAF2 and TRAF3 within the complex. Because TRAF2 and TRAF3 are involved in other signaling platforms, the NIK IBM may have a role in the regulation of a number of signaling pathways. Subsequently, loss or mutation of the NIK IBM results in insufficient complex formation, NIK stabilization, activation of the noncanonical NF-κB pathway, and possibly modulation of other signaling pathways (Fig. 5C).

Notwithstanding the fact that we have not directly tested binding affinity in this study, the specific binding of the NIK IBM to BIR2 of c-IAP1, and the ability to compete away NIK binding to c-IAP1 with Smac, could imply that the NIK IBM may have low binding affinity. This prediction might help explain how NIK dissociates from the complex following an activating signal. Furthermore, an IBM with weak binding affinity would protect cells from spontaneous apoptosis, which might occur after NIK stabilization if the NIK IBM could bind tightly to numerous BIR domains in various IAP proteins. However, the NIK IBM needs to be more closely interrogated to support these predictions.

Although our data suggest that the NIK IBM properly orients the component proteins in the c-IAP-TRAF complex to confer specificity for the E3 ubiquitin ligase activity of c-IAPs, NIK IBM binding to c-IAP1 may also play a role in activating the ligase activity of c-IAP1, although neither feature need be mutually exclusive. Indeed, c-IAP1 E3 ligase activity is tightly auto-regulated by a specific conformation in the inactive enzyme that places the CARD domain in close proximity to the RING (43). Thus, c-IAP1 must undergo conformational changes to become activated (43). Consequently, the NIK IBM may bind to BIR2 of c-IAP1 and induce a conformational change that activates c-IAP1, thereby leading to degradation of the c-IAP-TRAF2-TRAF3-NIK complex. Despite the fact that more work is necessary before this hypothesis can be fully addressed, there is precedence for endogenous IBM-containing, or small molecule, IAP antagonists inducing conformational changes in c-IAP1 that stimulate its E3 activity (44).
However, these scenarios lead to autoubiquitylation and proteasomal degradation of c-IAP1.

Although great strides have been made in the elucidation of noncanonical NF-κB regulatory paradigms, there is a need for clearer mechanistic studies into the regulation of NIK stability. In fact, comprehending how NIK protein levels are managed within the c-IAP-TRAF2-TRAF3-NIK complex is a major emphasis of research in the field (8). The identification and characterization of an IBM in the amino terminus of NIK, as shown here, provides an important step forward in our understanding of the regulation of NIK stability and of the noncanonical NF-κB signaling pathway as a whole.

Acknowledgments—We thank members of the Wright and Bratton laboratory for critical reading of the manuscript and for helpful discussion.

REFERENCES

1. Hayden, M. S., and Ghosh, S. (2011) NF-κB in immunobiology. Cell Res. 21, 223–244
2. Hayden, M. S., and Ghosh, S. (2008) Shared principles in NF-κB signaling. Cell 132, 344–362
3. Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R. T., Virelizier, J. L., and Dargemont, C. (1997) Nuclear localization of IκBα promotes active transport of NF-κB from the nucleus to the cytoplasm. J. Cell Sci. 110, 369–378
4. Chen, L. F., Fischle, W., Verdin, E., and Greene, W. C. (2001) Duration of nuclear NF-κB action regulated by reversible acetylation. Science 293, 1653–1657
5. Bista, P., Zeng, W., Ryan, S., Bailly, V., Browning, J. L., and Lukashev, M. E. (2010) TRAF3 controls activation of the canonical and alternative NF-κB by the lymphocyte β receptor. J. Biol. Chem. 285, 12971–12978
6. Morrison, M. D., Reiley, W., Zhang, M., and Sun, S. C. (2005) An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-κB signaling pathway. J. Biol. Chem. 280, 10018–10024
7. Wright, C. W., Rumble, J. M., and Duckett, C. S. (2007) CD30 activates both the canonical and alternative NF-κB pathways in anaplastic large cell lymphoma cells. J. Biol. Chem. 282, 10252–10262
8. Razani, B., Reichardt, A. D., and Cheng, G. (2011) Non-canonical NF-kappaB signaling activation and regulation: principles and perspectives. ImmunoL Rev. 244, 44–54
9. Sun, S. C. (2012) The noncanonical NF-κB pathway. ImmunoL Rev. 246, 125–140
10. Sun, S. C. (2011) Non-canonical NF-κB signaling pathway. Cell Res. 21, 71–85
11. de Leon-Boenig, G., Bowman, K. K., Feng, J. A., Crawford, T., Everett, C., Franke, Y., Oh, A., Stanley, M., Staben, S. T., Starovasnik, M. A., Wallweber, H. J., Wu, J., Wu, L. C., Johnson, A. R., and Hymowitz, S. G. (2012) The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site. Structure 20, 1704–1714
12. Basak, S., Kim, H., Kearns, J. D., Tergaonkar, V., O’Dea, E., Werner, S. L., Benedict, C. A., Ware, C. F., Ghosh, G., Verma, I. M., and Hoffmann, A. (2007) A fourth IκB protein within the NF-κB signaling module. Cell 128, 369–381
13. Silke, J., and Vaux, D. L. (2001) Two kinds of BIR-containing protein - inhibitors of apoptosis, or required for mitosis. J. Cell Sci. 114, 1821–1827
14. Salvesen, G. S., and Duckett, C. S. (2002) IAP proteins: blocking the road to death’s door. Nat. Rev. Mol. Cell Biol. 3, 401–410
15. Choi, Y. E., Butterworth, M., Malladi, S., Duckett, C. S., Cohen, G. M., and Bratton, S. B. (2009) The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J. Biol. Chem. 284, 12772–12782
16. Eckelman, B. P., and Salvesen, G. S. (2006) The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J. Biol. Chem. 281, 3254–3260
17. Csomas, R. A., Brady, G. F., and Duckett, C. S. (2009) Enhanced cytoprotective effects of the inhibitor of apoptosis protein cellular IAP1 through stabilization with TRAF2. J. Biol. Chem. 284, 20531–20539
18. Wu, G., Chai, J., Suber, T. L., Wu, J. W., Du, C., Wang, X., and Shi, Y. (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408, 1008–1012
19. Srinivasula, S. M., Hegde, R., Saleh, A., Datta, P., Shiozaki, E., Chai, J., Lee, R. A., Robbins, P. D., Fernandes-Alnemri, T., Shi, Y., and Alnemri, E. S. (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112–116
20. Wilkinson, J. C., Wilkinson, A. S., Scott, F. L., Csomas, R. A., Salvesen, G. S., and Duckett, C. S. (2004) Neutralization of Smac/Diablo by inhibitors of apoptosis (IAPs): a caspase-independent mechanism for apoptotic inhibition. J. Biol. Chem. 279, 51082–51090
21. Vaux, D. L., and Silke, J. (2005) IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell Biol. 6, 287–297
22. Deveraux, Q. L., and Reed, J. C. (1999) IAP family proteins—suppressors of apoptosis. Genes Dev. 13, 239–252
23. Srinivasula, S. M., and Ashwell, I. D. (2008) IAPs: what’s in a name? Mol. Cell 30, 123–135
24. Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J., Flygare, J. A., Fairbrother, W. J., Deshayes, K., Dixit, V. M., and Vucic, D. (2007) IAP antagonists induce auto ubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131, 669–681
25. Csomas, R. A., Wright, C. W., Gálbán, S., Öetjen, K. A., and Duckett, C. S. (2009) Two distinct signalling cascades target the NF-κB regulatory factor c-IAP1 for degradation. Biochem. J. 420, 83–91
26. Suzuki, T., and Varshavsky, A. (1999) Degradation signals in the lysine-asparagine sequence space. EMBO J. 18, 3017–3026
27. Samuel, T., Welsh, K., Lober, T., Togo, S. H., Zapata, J. L., and Reed, J. C. (2006) Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J. Biol. Chem. 281, 1080–1090
28. Muro, I., Fang, G., Gardella, K. A., Mahajan, I. M., and Wright, C. W. (2014) The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways. Cell Cycle 13, 1918–1927
29. Liu, Z., Sun, C., Olejniczak, E. T., Meadows, R. P., Betz, S. F., Oost, T., Herrmann, J., Wu, J. C., and Fesik, S. W. (2000) Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408, 1004–1008
30. Giglione, C., Boularot, A., and Meinnel, T. (2004) Protein N-terminal me

The NIK IBM Provides Substrate Recognition for c-IAP1
ubiquitin-proteasome system through direct substrate targeting. Proc. Natl. Acad. Sci. U.S.A. 110, 14284–14289

37. Wright, C. W., and Clem, R. J. (2002) Sequence requirements for Hid binding and apoptosis regulation in the baculovirus inhibitor of apoptosis Op-IAP. Hid binds Op-IAP in a manner similar to Smac binding of XIAP. J. Biol. Chem. 277, 2454–2462

38. Blankenship, J. W., Varfolomeev, E., Goncharov, T., Fedorova, A. V., Kirkpatrick, D. S., Izrael-Tomasevic, A., Phu, L., Arnott, D., Aghajan, M., Zobel, K., Bazan, J. F., Fairbrother, W. J., Deshayes, K., and Vucic, D. (2009) Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem. J. 417, 149–160

39. Demchenko, Y. N., Glebov, O. K., Zingone, A., Keats, J. J., Bergsagel, P. L., and Kuehl, W. M. (2010) Classical and/or alternative NF-κB pathway activation in multiple myeloma. Blood 115, 3541–3552

40. Staudt, L. M. (2010) Oncogenic activation of NF-κB. Cold Spring Harb. Perspect. Biol. 2, a000109

41. Fulda, S., and Vucic, D. (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11, 109–124

42. Wright, C. W., and Duckett, C. S. (2005) Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115, 2673–2678

43. Lopez, J., John, S. W., Tenev, T., Rautureau, G. J., Hinds, M. G., Francalanci, F., Wilson, R., Broemer, M., Santoro, M. M., Day, C. L., and Meier, P. (2011) CARD-mediated autoinhibition of cIAP1’s E3 ligase activity suppresses cell proliferation and migration. Mol. Cell 42, 569–583

44. Dueber, E., Schoeffler, A. J., Lingel, A., Elliott, J. M., Fedorova, A. V., Giannetti, A. M., Zobel, K., Maurer, B., Varfolomeev, E., Wu, P., Wallweber, H. J., Hymowitz, S. G., Deshayes, K., Vucic, D., and Fairbrother, W. J. (2011) Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334, 376–380